Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS)
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: Polycystic ovarian syndrome (PCOS) is one of the most common reproductive disorders with strong association with both insulin resistance and non-alcoholic fatty liver disease (NAFLD). To untangle the complex relationship between PCOS and NAFLD, we analyzed serum biomarkers of apoptosis, some adipokines and mRNA profiles in the visceral adipose tissue of obese patients with NAFLD who were also diagnosed with PCOS and compared to a group with NAFLD only. Methods: We included patients with biopsy-proven NAFLD and PCOS (N = 12) and BMI-matched biopsy-proven NAFLD patients without PCOS (N = 12). Expression levels of individual mRNAs and soluble serum biomarkers were compared by non-parametric Mann–Whitney test. The analysis also included Spearman rank correlation tests and multiple regression analysis. For co-correlated genes, the factor analysis was performed. Results: The total serum levels of apoptotic biomarker M30 were significantly elevated in PCOS patients with liver steatosis as compared to non-PCOS NAFLD controls (P < 0.02), pointing that androgen-dependent proapoptotic PCOS environment that may directly contribute to NAFLD progression in these patients. Similarly, hyperandrogenism may explain the observed PCOS-specific decrease (P < 0.04) in adipose LDLR mRNA expression that may be connected to the proneness of PCOS patients to NAFLD. The levels of mRNA encoding angiogenesis-associated GSK-3B interacting protein ninein were also significantly increased in the adipose tissue of NAFLD patients with PCOS (P < 0.007). Furthermore, the levels of resistin positively correlated with expression levels of LDLR and prothrombin time (PT). Conclusion: An androgen-dependent proapoptotic PCOS environment may directly contribute to NAFLD progression in these patients. Hyperandrogenism may explain an observed decrease in adipose LDLR mRNA expression. An inflammation-associated increase in the release of resistin into circulation might contribute to the prothrombotic state observed under conditions associated with insulin resistance, including PCOS. The studies of larger cohorts of NAFLD with and without PCOS patients are needed to further assess these potential interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947 · cited 1×
“Intuitively, one would assume insulin resistance to be always associated with obesity, but clinical evidence has revealed that it exists in both lean and obese women with PCOS [13,14].”
BackgroundTeede, H., Deeks, A., & Moran, L. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-41 · Cited by 1,565 · cited 2×
“This is especially true for women with visceral obesity [3,4].”
The effect of obesity on polycystic ovary syndrome: a systematic review and meta‐analysis
Lim, S. S., Norman, R. J., Davies, M. J., & Moran, L. J. (2013) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01053.x · Cited by 539 · cited 1×
“In particular, obesity significantly worsens all metabolic and reproductive outcomes of patients with PCOS except for hirsutism [6].”
BackgroundAdiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis
Toulis, K. A., Goulis, D. G., Farmakiotis, D., Georgopoulos, N. A., Katsikis, I., Tarlatzis, B. C., Papadimas, I., & Panidis, D. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp006 · Cited by 262 · cited 1×
“When PCOS and non-PCOS NAFLD groups were compared, no difference in the levels of resistin, adiponectin and insulin were observed, thus, confirming the findings of others [29,30] and pointing to the fact that the levels of these hormones are defined by underlying metabolic states and patient’s BMI, rather than by PCOS.”
Result
Cited by
Sanchez-Garrido, M. A., & Tena-Sempere, M. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.01.001 · Cited by 557
Apoptosis and non-alcoholic fatty liver diseases
Kanda, T., Matsuoka, S., Yamazaki, M., Shibata, T., Nirei, K., Takahashi, H., Kaneko, T., Fujisawa, M., Higuchi, T., Nakamura, H., et al. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i25.2661 · Cited by 270
Wu, J., Yao, X.-Y., Shi, R.-X., Liu, S.-F., & Wang, X.-Y. (2018) · Reproductive Health · doi:10.1186/s12978-018-0519-2 · Cited by 130
Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome
Wang, D., & He, B. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s362424 · Cited by 28
“68 However, it has also been shown that the rs328 and rs268 polymorphisms of the lipoprotein lipase gene do not affect the occurrence of NAFLD in women with PCOS and in women without PCOS.”
Metadata
- Authors
- Baranova, A., Tran, T. P., Afendy, A., Wang, L., Shamsaddini, A., Mehta, R., Chandhoke, V., Birerdinc, A., & Younossi, Z. M.
- Venue
- Journal of Translational Medicine
- Published
- 2013-05-31
- Volume
- 11
- Issue
- 1
- Pages
- 133-133
- ISSN
- 1479-5876 (ISSN-L)
- OpenAlex
- W2146086141
- Cited by
- 85
- References
- 4
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS). https://app.cochat.ai/papers/10.1186/1479-5876-11-133
- The paper
- Baranova, A., Tran, T. P., Afendy, A., Wang, L., Shamsaddini, A., Mehta, R., Chandhoke, V., Birerdinc, A., & Younossi, Z. M. (2013). Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS). Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-11-133
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.